A female patient in an intensive outpatient program who is taking sertraline (Zoloft) reports feeling like she is in a shell (emotional numbness); what additional treatment options can be tried?

Augmentation Strategy for Emotional Numbness on Sertraline After IOP

Add bupropion SR 150 mg once daily (increasing to 150 mg twice daily after 3 days if tolerated) to your current sertraline regimen to address the emotional blunting you are experiencing. This combination targets both serotonergic and dopaminergic/noradrenergic pathways and has demonstrated superior efficacy compared to other augmentation strategies. 1

Evidence Supporting Bupropion Augmentation

• Bupropion augmentation of SSRIs decreases depression severity more effectively than buspirone augmentation in patients who have not achieved adequate response to SSRI monotherapy. 1

• In the STAR*D trial, augmenting citalopram (a closely related SSRI to sertraline) with bupropion SR achieved remission rates of approximately 30% in patients who failed initial SSRI treatment. 1

• Discontinuation rates due to adverse events were significantly lower with bupropion augmentation (12.5%) compared to buspirone augmentation (20.6%; P < 0.001), indicating superior tolerability while maintaining comparable efficacy. 1

• The American College of Physicians found no significant difference between switching versus augmenting strategies overall, but augmentation allows you to retain any partial benefit from sertraline while addressing residual symptoms. 1

Specific Advantages for Emotional Numbness

• Bupropion specifically addresses motivational deficits, apathy, and emotional blunting that commonly persist despite adequate serotonergic coverage from SSRIs like sertraline. 2

• The medication's norepinephrine-dopamine reuptake inhibition complements sertraline's serotonergic activity, providing synergistic relief for the "shell-like" emotional detachment you describe. 2

• Bupropion has significantly lower rates of sexual dysfunction compared to SSRIs, which may further improve quality of life if this has been a concern. 1, 2

• Unlike sertraline, bupropion is associated with minimal weight gain or even modest weight loss, potentially offsetting any weight-related side effects from your current medication. 2

Dosing Protocol

• Start bupropion SR at 150 mg once daily in the morning for the first 3 days, then increase to 150 mg twice daily (total 300 mg) if tolerated. 2

• Administer the second dose before 3 PM to minimize insomnia risk, as bupropion has activating properties. 2

• Continue your current sertraline dose unchanged during the augmentation trial. 1

• Maximum bupropion dose is 400 mg/day for SR formulation (or 450 mg/day for XL), though most patients respond adequately to 300 mg/day. 2

Critical Safety Screening Before Starting

• Confirm you do not have a history of seizure disorders, eating disorders (bulimia/anorexia), or conditions predisposing to seizures (head trauma, brain tumor, stroke), as these are absolute contraindications to bupropion. 2

• Verify you are not taking MAOIs or have not taken them within the past 14 days, as this combination is contraindicated. 2

• Check baseline blood pressure and heart rate, as bupropion can cause modest elevations; uncontrolled hypertension is a contraindication. 2

• Screen for bipolar disorder or family history of mania/hypomania, as antidepressants including bupropion can precipitate manic episodes without mood stabilizer coverage. 3

Expected Timeline and Monitoring

• Allow 6–8 weeks at the therapeutic bupropion dose (300 mg/day) before declaring treatment failure, as this is the minimum duration needed to assess full antidepressant response. 1, 2

• Some improvement in energy and motivation may appear within the first few weeks, but definitive assessment of emotional numbness should wait until the 6–8 week mark. 2

• Monitor for suicidal ideation during the first 1–2 months after starting bupropion, as all antidepressants carry an FDA black-box warning for increased suicide risk in patients under 24 years, with the greatest risk during initial treatment and dose changes. 3

• Assess treatment response every 2–4 weeks using standardized depression rating scales (PHQ-9 or HAM-D) to objectively track symptom improvement. 4

Alternative Psychotherapy Augmentation

• Adding cognitive-behavioral therapy (CBT) to your medication regimen demonstrates superior efficacy compared to medication alone for depression and should be initiated immediately while optimizing pharmacotherapy. 1, 4

• CBT can be started without waiting for medication optimization, providing early psychological support for emotional processing deficits. 1

• The combination of CBT plus medication addresses both neurobiological and psychological components of your depression simultaneously. 4

Common Pitfalls to Avoid

• Do not switch medications before completing an adequate 6–8 week trial of the augmentation strategy, as premature changes delay recovery and miss opportunities for therapeutic response. 1

• Do not exceed bupropion 450 mg/day, as seizure risk increases markedly above this threshold (approximately 0.4% at 450 mg vs. 0.1% at 300 mg). 2

• Do not combine bupropion with other medications that lower seizure threshold without careful consideration and dose adjustments. 2

• Do not abruptly discontinue sertraline if you eventually need to switch medications, as SSRIs require gradual tapering to prevent discontinuation syndrome (dizziness, anxiety, irritability, sensory disturbances). 3

If Augmentation Fails After 8 Weeks

• Switch to an SNRI (venlafaxine 150–225 mg daily or duloxetine 40–120 mg daily) if bupropion augmentation does not yield adequate response after 8 weeks at therapeutic doses. 1, 5

• SNRIs have demonstrated statistically significant superior response and remission rates compared to SSRIs in treatment-resistant depression, though they carry higher discontinuation rates due to adverse effects. 1, 5

• Approximately 25% of patients achieve remission after switching from a failed SSRI to a different antidepressant class. 1

Duration of Continuation Therapy

• After achieving satisfactory response, continue the combination therapy for 4–9 months for a first episode of major depressive disorder to consolidate remission. 1

• For recurrent depression (≥2 episodes), consider maintenance therapy for years to lifelong to prevent relapse, as relapse risk rises to 70% after two episodes and 90% after three episodes. 1